Evidence map›Paper›PMID 36045676›Full record

ArticleFrontiers in immunology2022

Smad4-deficient T cells promote colitis-associated colon cancer

Sung Hee Choi, Alex Y Huang, John J Letterio, Byung-Gyu Kim

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Smad4 Deficiency in S100A4International journal of biological sciences · 2024
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Sung Hee ChoiCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, United States.
Alex Y HuangCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, United States.
John J LetterioCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, United States.
Byung-Gyu KimCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, United States.
Case Western Reserve University · USRainbow Babies & Children's Hospital · USUniversity School · US

Funding

Small Molecule Induction of 15-PGDH: A Target in Colon Cancer ChemopreventionR01CA168586 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI LETTERIO, JOHN JAMES · 2013 to 2017
$1.6M
Mechanisms of TGF-β-induced resistance to proteasome inhibitors in multiplemyelomaR03CA259901 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KIM, BYUNG-GYU · 2022 to 2023
$161k
NCI NIH HHS R01 CA168586NCI NIH HHS R03 CA259901
6 · The paper itself

Abstract

Immune cells and the cytokines they produce are important mediators of the transition from colitis to colon cancer, but the mechanisms mediating this disease progression are poorly understood. Interferon gamma (IFN-γ) is known to contribute to the pathogenesis of colitis through immune modulatory mechanisms, and through direct effects on endothelial and epithelial homeostasis. Here we explore whether IFN-γ influences tumor progression by expanding the effector memory T cells (T

Indexed as

Colitis-Associated NeoplasmsColonic NeoplasmsAnimalsColitisHumansHydroxyprostaglandin DehydrogenasesInterferon-gammaMiceSmad4 ProteinT-Lymphocytes15-hydroxyprostaglandin dehydrogenaseHydroxyprostaglandin DehydrogenasesIFNG protein, mouseInterferon-gammaSmad4 ProteinSMAD4 protein, humanSmad4 protein, mouse15-PGDHCD4 effector T cellcolitis-associated colon cancerIFN-gammaSmad4

Identifiers

PMID36045676
PMCPMC9420841
OpenAlexW4291382933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.